GlassScriptPhysician profile
Richard J Lee
NPI 1386640274
$3,118.86
in general payments reported to CMS, 2019-2025
18 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,206 · 2020: $496 · 2021: $571 · 2022: $660 · 2023: $33.57 · 2024: $153.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $186.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $186.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $668.59 | 2019-2024 | Ojjaara |
| Astrazeneca Pharmaceuticals LP | $662.82 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $304.88 | 2019-2022 | |
| Genzyme Corporation | $303.55 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $216.42 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $192.48 | 2019-2020 | |
| Genentech USA, INC. | $156.64 | 2019-2022 | |
| Amgen INC. | $123.00 | 2022 | |
| Alk-Abello, INC | $96.59 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $76.71 | 2021-2022 | |
| Optinose US, INC. | $76.13 | 2019 | |
| Pfizer INC. | $74.03 | 2019-2021 | |
| Kaleo, INC. | $40.22 | 2019-2020 | |
| Octapharma USA, INC. | $32.54 | 2019-2020 | |
| Phadia US INC. | $31.31 | 2019-2022 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $21.91 | 2019 | |
| Aimmune Therapeutics, INC. | $21.27 | 2021 | |
| Shire North American Group INC | $19.77 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Richard Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.